SK Biopharm Epilepsy New Drug 'Cenobamate' Receives Marketing Approval in Israel
SK Biopharm announced on the 3rd that the Israeli Ministry of Health approved the New Drug Application (NDA) for the epilepsy drug 'Cenobamate' (local product name Exkopri) on the 30th of last month.
![SK Biopharm Cenobamate. <br>[Photo by SK Biopharm]](http://www.asiae.co.kr/news/img_view.htm?img=2020052110194449766_1612134751.jpg)
This approval application was submitted by SK Biopharm's Israeli partner, Dexcel Ltd. A total of six dosages?12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg?were included in the approval.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- $800 Million Oil Trades Just Before Trump Announcement... U.S. Authorities Launch Investigation
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
- One Korean Vessel Passes Through Strait of Hormuz... Will Others Follow?
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
Based on this approval, SK Biopharm plans to accelerate its market expansion in West Asia, including Israel.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
